ZyCoV-D is a needle-free, plasmid DNA vaccine against SARS-CoV-2 developed indigenously by Zydus Cadila (now Zydus Lifesciences) of Ahmedabad, with partial funding from the Department of Biotechnology under the National Biopharma Mission and the Biotechnology Industry Research Assistance Council (BIRAC). On 20 August 2021 the Drugs Controller General of India (DCGI) granted it Emergency Use Authorisation (EUA), making it both the first DNA-based vaccine in the world approved for human use and the first COVID-19 vaccine in India cleared for the 12–18 age group. Its development is anchored in India's broader "Atmanirbhar Bharat" and Mission COVID Suraksha framework, which sought self-reliance in vaccine technology platforms.
Mechanistically, ZyCoV-D uses a circular fragment of plasmid DNA carrying the gene that codes for the spike (S) protein of SARS-CoV-2. Once introduced into human cells, the plasmid is transcribed and translated so that the body manufactures the spike antigen, triggering both humoral (antibody) and cellular immune responses without using any live or inactivated virus, viral vector, or mRNA. A distinguishing feature is its three-dose intradermal regimen administered via the PharmaJet Tropis, a spring-powered needle-free applicator that delivers the vaccine as a narrow fluid stream, reducing pain, adverse reactions at the injection site, and the cold-chain burden — the vaccine is reportedly stable at 2–8°C and tolerates 25°C for several months, easing distribution. DNA platforms are also attractive because the plasmid construct can be rapidly re-engineered against emerging variants.
The vaccine reported roughly 66.6% efficacy in its Phase III interim analysis, conducted across India during the Delta-variant wave in over 28,000 volunteers — among the largest trials of an Indian vaccine. Despite EUA, ZyCoV-D saw limited rollout in the national programme compared with Covishield and Covaxin, partly owing to its three-dose schedule and applicator logistics. Globally it remains a landmark proof-of-concept: it validated DNA vaccinology, long pursued in veterinary medicine, as viable for humans, paving the way for next-generation platforms. As of 2026, it stands principally as a scientific and strategic milestone in India's vaccine-innovation story rather than a mass-deployed product.
For the UPSC examination, ZyCoV-D is high-value material for the General Studies Paper III science-and-technology component, specifically under "developments in biotechnology" and "indigenisation of technology." Prelims questions typically test discrimination between vaccine platforms — candidates must distinguish DNA (ZyCoV-D), mRNA (Pfizer, Moderna), viral-vector (Covishield, Sputnik V), and inactivated-virus (Covaxin) approaches, and recall the unique "world's first DNA vaccine, needle-free, three-dose" attributes. Mains and interview angles probe India's self-reliance in vaccine R&D, the role of DBT–BIRAC and Mission COVID Suraksha, and the regulatory significance of DCGI's EUA process. Aspirants should also link it to intellectual-property, public-health-infrastructure, and the cold-chain logistics themes that recur in governance and economy papers.
Example
In August 2021, India's DCGI granted Emergency Use Authorisation to Zydus Cadila's ZyCoV-D, the world's first DNA-based COVID-19 vaccine, cleared for the 12–18 age group and delivered needle-free.
Frequently asked questions
It is the world's first DNA plasmid-based vaccine approved for human use. It is also needle-free, administered intradermally via the PharmaJet Tropis applicator, and uses a three-dose schedule rather than the conventional two doses.